These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 8152797

  • 1. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1.
    Huang RP, Darland T, Okamura D, Mercola D, Adamson ED.
    Oncogene; 1994 May; 9(5):1367-77. PubMed ID: 8152797
    [Abstract] [Full Text] [Related]

  • 2. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain.
    Huang RP, Liu C, Fan Y, Mercola D, Adamson ED.
    Cancer Res; 1995 Nov 01; 55(21):5054-62. PubMed ID: 7585551
    [Abstract] [Full Text] [Related]

  • 3. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
    Scharnhorst V, Menke AL, Attema J, Haneveld JK, Riteco N, van Steenbrugge GJ, van der Eb AJ, Jochemsen AG.
    Oncogene; 2000 Feb 10; 19(6):791-800. PubMed ID: 10698497
    [Abstract] [Full Text] [Related]

  • 4. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity.
    Liu C, Calogero A, Ragona G, Adamson E, Mercola D.
    Crit Rev Oncog; 1996 Feb 10; 7(1-2):101-25. PubMed ID: 9109500
    [Abstract] [Full Text] [Related]

  • 5. Imbalanced expression of cellular nuclear oncogenes caused by v-sis/PDGF-2.
    Sonobe MH, Bravo R, Armelin MS.
    Oncogene; 1991 Sep 10; 6(9):1531-7. PubMed ID: 1923519
    [Abstract] [Full Text] [Related]

  • 6. Reciprocal modulation between Sp1 and Egr-1.
    Huang RP, Fan Y, Ni Z, Mercola D, Adamson ED.
    J Cell Biochem; 1997 Sep 15; 66(4):489-99. PubMed ID: 9282327
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C, Fernandez-Medarde A, Rojas JM, Font de Mora J, Esteban LM, Santos E.
    Oncogene; 1998 Feb 05; 16(5):613-24. PubMed ID: 9482107
    [Abstract] [Full Text] [Related]

  • 10. Rapid, complete and reversible transformation by v-sis precedes irreversible transformation.
    Mercola D, Carpenter PM, Grover-Bardwick A, Mercola M.
    Oncogene; 1992 Sep 05; 7(9):1793-803. PubMed ID: 1501889
    [Abstract] [Full Text] [Related]

  • 11. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM.
    Nat Med; 2003 Aug 05; 9(8):1026-32. PubMed ID: 12872165
    [Abstract] [Full Text] [Related]

  • 12. Regulation of Egr-1-dependent gene expression by the C-terminal activation domain.
    Gosslar U, Schmid RM, Holzmann B.
    Biochem Biophys Res Commun; 1999 Feb 16; 255(2):208-15. PubMed ID: 10049687
    [Abstract] [Full Text] [Related]

  • 13. Activated mutant of G alpha 13 induces Egr-1, c-fos, and transformation in NIH 3T3 cells.
    Vara Prasad MV, Shore SK, Dhanasekaran N.
    Oncogene; 1994 Aug 16; 9(8):2425-9. PubMed ID: 8036026
    [Abstract] [Full Text] [Related]

  • 14. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
    Worden B, Yang XP, Lee TL, Bagain L, Yeh NT, Cohen JG, Van Waes C, Chen Z.
    Cancer Res; 2005 Aug 15; 65(16):7071-80. PubMed ID: 16103054
    [Abstract] [Full Text] [Related]

  • 15. A biological role for Egr-1 in cell survival following ultra-violet irradiation.
    Huang RP, Adamson ED.
    Oncogene; 1995 Feb 02; 10(3):467-75. PubMed ID: 7845671
    [Abstract] [Full Text] [Related]

  • 16. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
    Menke AL, Riteco N, van Ham RC, de Bruyne C, Rauscher FJ, van der Eb AJ, Jochemsen AG.
    Oncogene; 1996 Feb 01; 12(3):537-46. PubMed ID: 8637710
    [Abstract] [Full Text] [Related]

  • 17. Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells.
    Maroney AC, Qureshi SA, Foster DA, Brugge JS.
    Oncogene; 1992 Jun 01; 7(6):1207-14. PubMed ID: 1375718
    [Abstract] [Full Text] [Related]

  • 18. Regulation of Egr-1 (Zfp-6) and c-fos expression in differentiating embryonal carcinoma cells.
    Darland T, Samuels M, Edwards SA, Sukhatme VP, Adamson ED.
    Oncogene; 1991 Aug 01; 6(8):1367-76. PubMed ID: 1909429
    [Abstract] [Full Text] [Related]

  • 19. [The antibodies obtained by immunization with a peptide identical to a section of the zinc-binding domain of the early growth response 1 factor (EGR-1) interact with a 102-kDa protein from mouse fibroblasts].
    Popov BV, Kaczmarek L.
    Tsitologiia; 1994 Aug 01; 36(5):453-8. PubMed ID: 7809981
    [Abstract] [Full Text] [Related]

  • 20. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells.
    Potapova O, Fakhrai H, Baird S, Mercola D.
    Cancer Res; 1996 Jan 15; 56(2):280-6. PubMed ID: 8542581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.